 |
|
ESC Congress 2004: Brazilian Study suggests intramyocardial injection of cells from bone marrow might be an alternative for heart transplantation in end-stage heart failure due to coronary disease
August 30, 2004Cardiovascular disease remains the leading cause of morbidity and mortality around the world and patients with end-stage ischemic heart failure carry the highest morbid-mortality rate. Although heart transplant improves the outcomes of selected patients, the donor heart availability has limited its widespread utilization. Autologous bone marrow mononuclear cells transplantation through intramyocardial injections has been used in very initial clinical trials with promising results for treating these patients.
Our study was carried out at Pr'³-Card'aco Hospital with the financial support of the Filantropic Foundation for Teaching and Researching of Pr'³-Card'aco Hospital (PROCEP), in Rio de Janeiro, Brazil. The catheter-based injection system (NOGA system, Cordis Johnson&Johnson) was handled by Dr Emerson Perin from Texas Heart Institute, Houston, who was the co-principal investigator in this study.
Twenty-one patients were enrolled in this clinical trial started in December 2001, which was conducted at Pr'³-Card'aco Hospital, in Rio de Janeiro, Brazil, in a partnership with Texas Heart Institute, Houston, and the Federal University of Rio de Janeiro.
It is important to emphasize that this trial was preceded by experimental models developed in partnership with the Federal University of Rio de Janeiro, granted by the Brazilian Ministry of Science and Technology. The clinical trial was approved by the Hospital Pr'³-card'aco ethics committee and the Brazilian Research Ethics Council.
All patients had severe ischemic heart failure not amenable to any revascularization procedure. Fourteen patients were submitted to injections of autologous bone marrow mononuclear cells into myocardial safely, as our previously published data. The seven other patients served as a comparison or control group, and did not receive injections up to one year follow up. Our main objective was to create new small vessels in myocardial areas that were not receiving enough blood supply and because of that were contracting badly.
According to our published results, the treated patients had a significant 71% reduction in the amount of cardiac muscle with impaired blood supply and an improvement in the mechanical function, compared to the control group.
We came to this ESC Congress to report results from a subgroup of 5 treated patients that were already listed for heart transplantation and we could observe the same benefit that was seen in the entire group, including functional capacity and quality of life improvement.
We had already reported a six month follow up of such five patients in the 2003 ESC Congress, but there were concerns about the fading of benefits initially observed.
Nevertheless it is intriguing that the exercise capacity not only improved significantly but also reached such threshold that 4 from 5 patients were no longer eligible for cardiac transplantation up to one year follow up.
We have an ongoing post-mortem anatomopathological analysis and immunohistochemical findings from one patient who died at 11 months follow up due to stroke (not from the heart transplantation list) that will give us further understanding of cell mechanisms and behavior after transplantation in humans.
My words from 2003 regarding the social relevance of this finding still seems to be very promising since there is not a single heart transplant program anywhere in the world which is able to treat all the patients who need it.
We all are eagerly awaiting larger clinical trials that could confirm our results, which could lead to a revolutionary treatment for all these end-stage patients on the heart transplantation waiting list.
HF Dohmann (Rio de Janeiro, BR)
*****
This press release accompanies both a presentation and an ESC press conference given at the ESC Congress 2004. Written by the investigator himself/herself, this press release does not necessarily reflect the opinion of the European Society of Cardiology
European Society of Cardiology (ESC)
It is important to emphasize that this trial was preceded by experimental models developed in partnership with the Federal University of Rio de Janeiro, granted by the Brazilian Ministry of Science and Technology. The clinical trial was approved by the Hospital Pr'³-card'aco ethics committee and the Brazilian Research Ethics Council.
All patients had severe ischemic heart failure not amenable to any revascularization procedure. Fourteen patients were submitted to injections of autologous bone marrow mononuclear cells into myocardial safely, as our previously published data. The seven other patients served as a comparison or control group, and did not receive injections up to one year follow up. Our main objective was to create new small vessels in myocardial areas that were not receiving enough blood supply and because of that were contracting badly.
According to our published results, the treated patients had a significant 71% reduction in the amount of cardiac muscle with impaired blood supply and an improvement in the mechanical function, compared to the control group.
We came to this ESC Congress to report results from a subgroup of 5 treated patients that were already listed for heart transplantation and we could observe the same benefit that was seen in the entire group, including functional capacity and quality of life improvement.
We had already reported a six month follow up of such five patients in the 2003 ESC Congress, but there were concerns about the fading of benefits initially observed.
Nevertheless it is intriguing that the exercise capacity not only improved significantly but also reached such threshold that 4 from 5 patients were no longer eligible for cardiac transplantation up to one year follow up.
We have an ongoing post-mortem anatomopathological analysis and immunohistochemical findings from one patient who died at 11 months follow up due to stroke (not from the heart transplantation list) that will give us further understanding of cell mechanisms and behavior after transplantation in humans.
My words from 2003 regarding the social relevance of this finding still seems to be very promising since there is not a single heart transplant program anywhere in the world which is able to treat all the patients who need it.
We all are eagerly awaiting larger clinical trials that could confirm our results, which could lead to a revolutionary treatment for all these end-stage patients on the heart transplantation waiting list.
HF Dohmann (Rio de Janeiro, BR)
*****
This press release accompanies both a presentation and an ESC press conference given at the ESC Congress 2004. Written by the investigator himself/herself, this press release does not necessarily reflect the opinion of the European Society of Cardiology
European Society of Cardiology (ESC)
Heart Failure Current Events and Heart Failure News RSSNew hope for cancer comes straight from the heart
Digitalis-based drugs like digoxin have been used for centuries to treat patients with irregular heart rhythms and heart failure and are still in use today. In the Dec. 16 issue of the Proceedings of the National Academy of Sciences, researchers at the Johns Hopkins University School of Medicine now report that this same class of drugs may hold new promise as a treatment for cancer.
New appropriate use criteria guide treatment of patients with heart blockage
If you're committed to fitness, the decision to climb a couple of flights of stairs rather than take the elevator is clear. But if you develop chest pain on the way up, deciding how to treat the symptoms of clogged arteries in your heart is much more complicated.
Arousal frequency in heart failure found to be a unique sleep problem
A study in the Jan. 1 issue of the journal Sleep demonstrates that the frequent arousals from sleep that occur in heart failure patients with central sleep apnea (CSA) may reflect the presence of another underlying arousal disorder rather than being a defensive mechanism to terminate apneas.
Simple Model Predicts Those at Risk for Chronic Kidney Disease
Traditionally, doctors have had no clear way to predict which of their patients might be headed down the road to chronic kidney disease (CKD).
Implantable monitor may help in managing diastolic heart failure
An implantable hemodynamic monitor (IHM) may help to guide medical treatment in a large subgroup of patients with heart failure-those with diastolic heart failure (DHF).
Study finds treatment fails to improve common form of heart failure
A medication used for high blood pressure does not improve a common form of heart failure, according to new results from a large, international study.
Vitamin E shows possible promise in easing chronic inflammation
With up to half of a person's body mass consisting of skeletal muscle, chronic inflammation of those muscles - which include those found in the limbs - can result in significant physical impairment.
Fruit fly research may lead to better understanding of human heart disease
Researchers at the Burnham Institute for Medical Research (Burnham) have shown in both fruit flies and humans that genes involved in embryonic heart development are also integral to adult heart function. The study, led by Rolf Bodmer, Ph.D., was published in Proceedings of National Academy of Sciences.
Mini heart attacks lessen damage from major ones
Researchers have discovered one potential mechanism by which briefly cutting off, then restoring, blood flow to arteries prior to a heart attack lessens the damage caused, according to a study published today in the journal Cardiovascular Research.
Mechanisms of cardiovascular disease and cancer give clues to new therapies
Cardiovascular conditions leading to heart attacks and strokes are treated quite separately from common cancers of the prostate, breast or lung, but now turn out to involve some of the same critical mechanisms at the molecular level.
More Heart Failure Current Events and Heart Failure News Articles
 | Success with Heart Failure (mass mkt ed): Help and Hope for Those with Congestive Heart Failure by Marc Silver Up-to-date information on available and forthcoming medical and surgical treatments. How attitude and emotion affect heart failure--and what you can do to stay positive. Tips for adopting a heart-healthy diet and lifestyle. Ways to forge a positive working relationship with your doctor or cardiologist.... |
 | Clinical Management of Heart Failure, Second Edition by James B. Young, Roger M. Mills The various classes of medications employed in the treatment of heart failure are reviewed as well as the clinical trials shaping heart failure therapeutics. Appropriate staging of therapeutics is discussed along with rational polypharmacy. Treatment options for advanced heart failure are concisely... |
 | Heart Failure: A Practical Approach to Treatment by William Abraham, Henry Krum The definitive one-stop guide to treating -- and preventing -- heart failure. . This practical reference provides all the expert guidance and up-to-the-minute clinical perspectives you need to diagnose, treat, and manage patients with heart failure.. A major focus of the book is integration of various management approaches to maximize patient benefit. Coverage begins with a brief introduction... |
 | MemoCharts Pharmacology: Drug Therapy for Congestive Heart Failure (Review chart) by Howard Shen |
 | Resynchronization and Defibrillation for Heart Failure: A Practical Approach by David L. Hayes, Paul J. Wang, Jonathan Sackner-Bernstein, Samuel J. Asirvatham Resynchronization and Defibrillation for Heart Failure: A Practical Approach is one of the first texts to provide caregivers with information about the background and application of this new and rapidly expanding discipline. Its five authors are cardiologists who have expertise in device management, electrophysiology, and heart failure management. The text integrates the approach and management... |
 | Atlas of Electrophysiology in Heart Failure Heart Failure has emerged as a major cardiovascular health problem. Clinical cardiology has become progressively subdivided into more highly specialized domains, yet the modern management of the heart failure patient crosses these boundaries. Given the cross-disciplinary nature of heart failure management, the Atlas of Electrophysiology in Heart Failure, which explores current concepts in the... |
 | Heart Failure: Pathophysiology, Molecular Biology, and Clinical Management (HEART FAILURE: PATHOPHYSIOLOGY, MOLEC BIOL & CLIN MGT) by Arnold M Katz, Marvin A Konstam This Second Edition of Dr. Katz's highly acclaimed text has been thoroughly revised to incorporate the latest advances in the study and treatment of heart failure. The book explains the pathophysiology, molecular mechanisms, clinical manifestations, and therapy of heart failure in an integrated, reader-friendly manner that is accessible to both clinicians and basic scientists. More than 100... |
 | Heart Failure: A Clinical Nursing Handbook (Wiley Series in Nursing) by Christopher Nicholson This book provides a complete, easy-to-use handbook for nurses who see patients with heart failure. In recent years heart failure has become a high priority in health care. With more nurses caring for patients with heart failure and making decisions that are often complex, there is a clear need for those nurses to have access to good quality clinical information and guidance. This book is... |
 | Heart Failure in the Elderly, An Issue of Heart Failure Clinics (The Clinics: Internal Medicine) by W. S. Aronow |
 | Diastology: Clinical Approach to Diastolic Heart Failure by Allan L. Klein, Mario J. Garcia This reference thoroughly equips you to successfully diagnose and manage even the most complex incidences of diastolic heart failure and their comorbidities. It examines the basic mechanisms of this condition through discussions of both cellular and anatomic causes; guides you through non-invasive techniques for diagnosis, including echocardiography, cardiac CT, and MRI; and provides expert... |
| © 2009 BrightSurf.com |